YN1548: A novel small-molecule agonist of human glucagon-like peptide-1 receptor for the treatment of type 2 diabetes mellitus and obesity
1. 系统已在2026-08-11 11:47:06对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
IG Je, TK Kim, HJ Lee, MY Lee, KM An, JT Park…
European Journal of …, 2025
Elsevier
Type 2 diabetes mellitus (T2DM) and obesity are the major global health concerns. Glucagon-like peptide-1 (GLP-1) receptor agonists are effective incretin-based treatments for T2DM and obesity. The patient compliance of peptide-based GLP-1 receptor agonists is limited due to subcutaneous administration. This study aimed to develop small-molecule GLP-1 receptor agonists that can be administered orally. Pharmacological properties of YN1548 were evaluated using in vitro assays in Chinese hamster ovary (CHO) cells …

